ImClone Receives $70 A Share Buyout Offer, Rejects Bristol-Meyer Offer


Email Facebook Digg Twitter Buzz Up! ShareThis

September 10, 2008 3:21 p.m. EST

Topics: Business
Mitchell Jaworski - AHN Reporter

New York, NY (AHN) - ImClone Systems Inc announced Wednesday it received a buyout offer of $70 a share from a large pharmaceutical company. The offer tops Bristol-Myers Squibb Co's offer of $60 a share.

Shares of ImClone jumped 7 percent on the buyout news to $68.15. When Bristol-Myers made their $60 a share offer back on July 30, ImClone shares were trading at $46.44.

The $70 a share offer from the unnamed pharmaceutical company values ImClone at roughly $6.1 billion.

Rumors have already begun to swirl on the identity of the buyer; Merck, Sanofi Aventis and Takeda are all large pharmaceuticals whose names have been mentioned.

ImClone said in a statement they will let the new bidder conduct due-diligence for a two week period.

Carl Icahn, the Chairmen of ImClone's board has preached for several months that the company is worth $80 a share.

The one caveat for any potential buyer is that Bristol-Myers owns a 20 percent stake in ImClone and markets their blockbuster cancer drug, Erbitux in the U.S., where it receives 60 percent of the drug's revenue. This fact naturally made Bristol-Myers the best candidate to buy ImClone, however, they were not willing to pay ImClone's asking price.


Copyright © 2003 - 2010 AHN - All rights reserved.
Redistribution, republication. syndication, rewriting or broadcast is prohibited without the prior written consent of AHN.
License AHN news for your website, business, digital signage network or publication.

 

Recent Comments

Popular Threads